SHR-1918 placebo

DRUG4 trials

Sponsors

Beijing Suncadia Pharmaceuticals Co., Ltd

Conditions

Homozygous Familial HypercholesterolemiaHyperlipemiaHyperlipidemiaHyperlipidemic

Phase 1

Safety and Tolerability of SHR-1918 in Healthy Subjects

Beijing Suncadia Pharmaceuticals Co., LtdHyperlipemia

Start: 2022-06-27End: 2023-12-12Updated: 2023-07-06

Phase 2

Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemic

CompletedNCT06109831

Beijing Suncadia Pharmaceuticals Co., LtdHyperlipidemic

Start: 2023-11-24End: 2025-07-04Updated: 2026-02-02

Phase 3

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia

CompletedNCT06723652

Beijing Suncadia Pharmaceuticals Co., LtdHomozygous Familial Hypercholesterolemia

Start: 2025-02-13End: 2025-11-18Updated: 2025-12-15

A Trial to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia

RecruitingNCT07230730

Beijing Suncadia Pharmaceuticals Co., LtdHyperlipidemia

Start: 2026-01-13End: 2027-10-01Target: 900Updated: 2026-09-10

Related Papers

SHR-1918, A Monoclonal Antibody Against Angiopoietin-Like 3, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Study.

2025-06-273 citations

Angiopoietin-Like 3 Antibody Therapy in Patients With Suboptimally Controlled Hyperlipidemia: A Phase 2 Study.

2025-03-316 citations

SHR-1918, a monoclonal antibody against angiopoietin-like 3, in healthy subjects: a randomized, double-blind, placebo-controlled, phase 1 study

European Heart Journal2024-10-014 citations